News & Updates
Filter by Specialty:
Nerandomilast slows IPF progression in patients already on antifibrotic therapy
The novel oral PDE4B* inhibitor nerandomilast slows the progression of idiopathic pulmonary fibrosis (IPF) in patients receiving antifibrotic treatment, as shown in the phase III FIBRONEER-IPF trial.
Nerandomilast slows IPF progression in patients already on antifibrotic therapy
11 Jul 2025
Lorundrostat for uncontrolled hypertension hits efficacy, safety targets in phase III trial
Twelve weeks of treatment with the aldosterone synthase inhibitor lorundrostat proved efficacious and safe for lowering blood pressure (BP) in adults with uncontrolled hypertension, including those who were resistant to treatment, according to the phase III Launch-HTN trial.
Lorundrostat for uncontrolled hypertension hits efficacy, safety targets in phase III trial
10 Jul 2025
Deucravacitinib delivers superior efficacy, safety in active PsA
Deucravacitinib exhibits superiority over placebo in terms of overall disease activity measures, musculoskeletal and dermatologic manifestations, and quality of life in adults with active psoriatic arthritis (PsA) who are naïve to biologic disease-modifying antirheumatic drugs (DMARDs), according to the results of the POETYK PsA-1 study.
